Healthy Returns

Improving Cancer Surgery with Ferronova's Precision ImagingIn this episode of Healthy Returns, we sit down with Stewart Bartlett, CEO of Ferronova, to explore how innovative imaging technology is transforming cancer surgery. Stewart shares insights into how Ferronova's nanoparticle-based approach can improve patient outcomes, reduce overtreatment, and potentially save lives.Key Topics:The unmet needs in oesophageal and stomach cancer treatmentHow Ferronova's iron oxide nanoparticle technology works during surgeryThe significance of lymph node mapping in cancer metastasisResults from clinical trials with 100% accuracy in identifying targeted lymph nodesRegulatory roadmap in Australia and Europe, expecting approval in 3-4 yearsMarket potential driven by healthcare economics, with treatment recurrence costs reaching $430,000 in the USCompetitive landscape and comparison to radiopharmaceutical diagnosticsTimestamps: 00:00 - Introduction and episode overview 00:27 - Stewart Bartlett's background in engineering and medtech 01:05 - Ferronova's focus on precision imaging for cancer surgery 01:44 - The origin of Ferronova from university research 02:11 - Unmet needs in oesophageal and stomach cancer treatments 02:52 - The nanoparticle technology for lymph node mapping 03:48 - Overcoming challenges of chemotherapy and radiotherapy 04:11 - MRI visibility and magnetic detector during surgery 04:54 - Surgical application of Ferronova's device 05:16 - How the system targets and drains lymph nodes 05:45 - Clinical trial progress and accuracy results 06:23 - Next steps and timeline for regulatory approval 06:58 - Estimated timeframe of three to four years for market readiness 07:49 - Market potential and economic benefits of reducing recurrence costs 08:23 - Comparison with radiopharmaceutical diagnostics 09:02 - Final thoughts and closing Resources & Links:Ferronova Official WebsiteIron Oxide Nanoparticles ExplainedClinical Trials Data --ENDS--